trial summary · NCT07069699
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
Trial record from the TrialBase DB dataset, status RECRUITING, condition Burkitt Lymphoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.
Source record: https://clinicaltrials.gov/study/NCT07069699
Facts
| registry id | NCT07069699 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Burkitt Lymphoma |
| sponsor | National Cancer Institute (NCI) |
| sponsor class | NIH |
| enrollment | 50 |
| start date | 2027-01-11 |
| primary completion | 2030-01-31 |
| completion | 2030-01-31 |
| results posted | not reported |
Conditions
- Burkitt Lymphoma
- Double-Expressor Lymphoma
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Interventions
- Biopsy Procedure
- Biospecimen Collection
- Computed Tomography
- Lumbar Puncture
- Pidnarulex
- Positron Emission Tomography
Countries
- United States
Intervention types: DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.